Skip to Main Content


Diseases of the Cardiovascular System | Diseases of the Nervous System, Phase III

Anticoagulation for Stroke Prevention and Recovery After ICH (ASPIRE)

What is the purpose of this trial?

Brief Summary:

Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF).

Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.

Contact Information

For more information about this study, including how to volunteer, contact Michael Kampp

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact, or call 877.978.8343 for more information.

  • Last Updated
  • Study HIC